Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
PHASE4
10 participants
INTERVENTIONAL
2021-12-01
2023-02-22
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
DISmantling COvid iNduced Neutrophil ExtraCellular Traps (DISCONNECT-1)
NCT04409925
Study to Investigate Long-term Pulmonary and Extrapulmonary Effects of COVID-19
NCT04581135
Early Treatment Strategy With High-dose Dexamethasone in Patients With SARS-CoV-2
NCT05293210
Colchicine Counteracting Inflammation in COVID-19 Pneumonia
NCT04322565
Cardiovascular Disease Progression in Survivors of Community Acquired Pneumonia and Lung Infection by Covid-19.
NCT06601998
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
4% saline
4% Saline inhalations twice daily
Saline
inhalations twice daily
Pulmosyme
DNAse alpha inhalations twice daily
Dornase Alfa
inhalations twice daily
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Dornase Alfa
inhalations twice daily
Saline
inhalations twice daily
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* inflamatory phase of infection
* HFNO
Exclusion Criteria
* previous treatment with DNAse alfa
18 Years
100 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University Medical Centre Ljubljana
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Marko Zlicar
Head of department
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University Medical Centre Ljubljana
Ljubljana, , Slovenia
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
DTS_pulmosyme
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.